Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference  
6/12/2014 8:15:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GOTHENBURG, Sweden--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of new KALYDECO™ (ivacaftor) data at the 37th European Cystic Fibrosis Society (ECFS) Conference, June 11-14, 2014, in Gothenburg, Sweden. New data from an analysis of Phase 3 and long-term extension studies in people with cystic fibrosis (CF) who have the G551D mutation showed that treatment with KALYDECO reduced the annual loss of lung function by half over three years compared to similar untreated CF patients. In addition, the first data from a rollover study following the Phase 3 KONDUCT study in people with the R117H mutation confirmed earlier results that demonstrated lung function improvements in people ages 18 and older. New data were also presented for the first time from the second part of the Phase 3 KONNECTION study in people with certain non-G551D gating mutations and showed that previously reported lung function improvements were maintained through 24 weeks of treatment.

Help employers find you! Check out all the jobs and post your resume.